Rijksinstituut voor Volksgezondheid en Milieu (RIVM)
Nationaal Kompas Volksgezondheid
Zoeken

Osteoporose

Kort en bondig

De ziekte, de determinanten en de zorg voor de patiënt

Omvang van het probleem

Geografische verschillen

Kijk ook eens bij:

Kijk ook eens bij andere websites:

.

Bronnen en Literatuur

Bronnen

Literatuur

  • Baan CA, van Baal PH, Jacobs-van der Bruggen MA, Verkley H, Poos MJ, Hoogenveen RT, Schoemaker CG. Diabetes mellitus in Nederland: schatting van de huidige ziektelast en prognose voor 2025. [Diabetes mellitus in the Netherlands: estimate of the current disease burden and prognosis for 2025]. Ned Tijdschr Geneeskd2009c; 153(22): 1052-8
  • Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, et al.Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA, 2002; 287: 847-57.
  • Black DM, Arden NK, Palermo L, Pearson J, Cummings SR.Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999; 14: 821-8.
  • Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al.Randomised trial effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41.
  • Burger H, Daele PLA van, Algra D, Hofman A, Grobbee DE, Schütte HE, et al.Vertebral deformities as predictors of non-vertebral fractures. BMJ 1994b; 309: 991-2.
  • Burger H, Daele PLA van, Grashuis K, Hofman A, Grobbee DE, Schütte HE, et al.Vertebral deformities and functional impairment in men and woman. J Bone Miner Res 1997; 12: 152-7.
  • Cauley JA, Cummings SR, Seeley DG, Black D, Browner W, Kuller LH, et al.Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1993; 118: 666-73.
  • Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al.Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65: 125-34.
  • CBO, Kwaliteitsinstituut voor de Gezondheidszorg. Osteoporose: Tweede Herziene Richtlijn. Utrecht: CBO,2002a.
  • Clemons M, Goss P.Estrogen and the risk of breast cancer. N Engl J Med 2001; 344: 276-85.
  • Collaborative Group on Hormonal Factors in Breast Cancer.Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047-59.
  • Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ III.Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 1992b; 7: 221-7.
  • Cummings SR, Black DM, Nevitt MC, et al.Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341: 72-5.
  • Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al.Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82.
  • Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ.Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985; 7: 178-205.
  • CVZ, College voor Zorgvezekeringen. Farmacotherapeutisch Kompas. Diemen,2008.
  • Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al.Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med, 1997; 337: 1641-7.
  • EC, European Commission.Rapport over osteoporose in de Europese Gemeenschap, Preventief handelen. Luxemburg: Bureau voor officiële publicaties der Europese Gemeenschappen, 1999.
  • EPOS, The European Prospective Osteoporosis Study Group.Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). Journal of Bone and Mineral Research 2002; 17(4): 716-724.
  • Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al.Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-45.
  • Ettinger B, Genant HK, Cann CE.Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985; 102: 319-24.
  • Gezondheidsraad.Preventie van osteoporose. Den Haag: Gezondheidsraad, 1991a.
  • Gold DT.The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 1996; 18: 185S-189S.
  • Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al.Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA, 1999a; 282: 1344-52.
  • Ioannidis JP, Ralston SH, Bennett ST, Brandi ML, Grinberg D, Karassa FB, et al.Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA, 2004 ; 292(17): 2105-2114.
  • Jacobs HS.Hormone replacement therapy and breast cancer. Endocr Relat Cancer 2000; 7: 53-61.
  • Johnell O, Kanis JA.An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int, 2006; 17: 1726-1733.
  • Kanis JA.Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994; 4: 368-81.
  • Klift M van der, Laet CEDH de, McCloskey EV, Hofman A, Pols HAP.The incidence of vertebral fractures in men and women: The Rotterdam Study. J Bone Miner Res, 2002; 17: 1051-6.
  • Laet CE de, Klift M van der, Hofman A, Pols HAP.Osteoporosis in men and women: a story about bone mineral density thresholds and hip fracture risk. J Bone Miner Res 2002; 17: 2231-6.
  • Laet CEDH de, Hout BA van, Burger H, Hofman A, Pols HAP.Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 1997; 315: 221-225.
  • Laet CEDH de, Hout BA van, Pols HAP.Osteoporosis in The Netherlands. IMTA publications, 1996a.
  • Lane NE, Haupt D, Kimmel DB, Modin G, Kinney JH.Early estrogen replacement therapy reverses the rapid loss of trabecular bone volume and prevents further deterioration of connectivity in the rat. J Bone Miner Res 1999; 14: 206-14.
  • Law MR, Wald NJ, Meade TW.Strategies for prevention of osteoporosis and hip fracture. BMJ 1991b; 303: 453-9.
  • Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, et al.Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res, 1998; 13: 1747-54.
  • Marshall D, Johnell O, Wedel H.Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254-59.
  • McClung MR, et al.Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med, 2001; 344(5): 333-40.
  • Melton LJ 3rd, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL.Epidemiology of vertebral fractures in women. Am J Epidemiol 1989; 129: 1000-11.
  • Michaelsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG, et al.Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ, 1998; 316: 1858-63.
  • Naessen T, Persson I, Adami HO, Bergstrom R, Bergkvist L.Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. Ann Intern Med 1990; 113: 95-103.
  • Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD.Postmenopausal hormone replacement therapy: scientific review. JAMA 2002a; 288: 872-81.
  • Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, et al.The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med, 1998; 128: 793-800.
  • Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C.Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 2000; 15: 1384-92.
  • O'Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ.The prevalence of vertebral deformity in European men and women: the European vertebral osteoporosis study. J Bone Miner Res 1996; 11: 1010-1018.
  • Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al.Alendronate for the treatment of osteoporosis in men. N Engl J Med, 2000; 343: 604-10.
  • Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, et al.Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int, 1999; 9: 461-8.
  • Poos MJJC, Smit JM, Groen J, Kommer GJ, Slobbe LCJ. Kosten van ziekten in Nederland 2005. RIVM-rapport nr. 270751019. Bilthoven: RIVM,2008.
  • Ralston SH, Uitterlinden AG, Brandi ML, Balcells S, Langdahl BL, Lips P, et al.Large-scale evidence for the effect of the COLIA1 Sp1 polymorphism on osteoporosis outcomes: the GENOMOS study. PLoS Medicine, 2006 ; 3(4): e90.
  • Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al.Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int, 2000; 11(1): 83-91.
  • Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, Wilson SG, et al.Genome-Wide Association Study Reveals Genetic Variants Associated with Bone Mineral Density, Osteoporosis and Osteoporotic Fractures. The Lancet, 2008; 371: 1505-1512.
  • Ross PD, Davis JW, Epstein RE, et al.Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114: 919-923.
  • Ross PD, Genant HK, Davis JW, Miller PD, Wasnich RD.Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos Int 1993; 3: 120-6.
  • Ross PD.Clinical consequences of vertebral fractures. Am J Med 1997; 103: 30S-42S; discussion 42S-43S.
  • Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, et al.Multiple genetic loci for bone mineral density and fractures. New England Journal of Medicine, 2008 ; 358(22): 2355-2365.
  • Uitterlinden AG, Ralston SH, Brandi ML, Carey AH, Grinberg D, Langdahl BL, et al.The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. Annals of Internal Medicine, 2006 ; 145(4): 255-264.
  • Van Meurs JB, Trikalinos TA, Ralston SH, Balcells S, Brandi ML, Brixen K, et al.Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA, 2008 ; 299(11): 1277-1290.
  • Writing Group for the PEPI Trial.Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA, 1996; 276: 1389-96.

Begrippen en afkortingen

Afkortingen

EU
Europese unie
ICD
International Classification of Diseases
Internationale classificatie van ziekten.
ICPC
International classification of primary care
NSAID
Non-steroidal anti-inflammatory drug
SD
Standaarddeviatie
SEH
Spoedeisende hulp
WHO
World Health Organization
Wereldgezondheidsorganisatie. URL: http://www.who.int

Definities

Incidentie
Het aantal nieuwe gevallen van of nieuwe personen met een bepaalde ziekte in een bepaalde periode, absoluut of relatief.
Prevalentie
Het aantal gevallen of personen met een bepaalde ziekte op een bepaald moment (punt-prevalentie) of in een bepaalde periode, bijvoorbeeld per jaar (periode-prevalentie), absoluut of relatief.
Standaardisatie
Het vergelijkbaar maken van cijfers (bijvoorbeeld sterftecijfers) die betrekking hebben op verschillende jaren of populaties, door rekening te houden met verschillen in bijvoorbeeld leeftijdsverdeling. Een veel gebruikte methode is zogenaamde 'directe standaardisatie', die de leeftijdsspecifieke cijfers van een populatie (de 'indexpopulatie') toepast op de leeftijdsverdeling van een gekozen 'standaardpopulatie'.
Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. Bilthoven: RIVM, <http://www.nationaalkompas.nl> versie 4.6.1, 31 januari 2012